Boots has announced it will start prescribing medical cannabis in the UK, in a first for a high street pharmacy, through its online SureLeaf service for patients aged 25 and over with eligible conditions such as chronic pain, anxiety or insomnia.
The pharmacy chain said patients will be invited to start an assessment online, after which a clinical team will review their suitability before they are invited to a video consultation with a consultant. Boots said any prescription would be “independently reviewed by a multidisciplinary clinical team that includes a second, independent consultant, before treatment begins”. Boots said patients wishing to be prescribed medical cannabis must first have tried conventional treatments without success and would be regularly reviewed.
Boots chief healthcare officer Jamie Kerruish said: “Millions of people live with ongoing pain and, for some, conventional treatments do not provide adequate symptom relief. This can have a significant impact on everyday life, from working and sleeping well to spending time with family and doing the things they enjoy.”
Dr David Gwynne, medical director of Boots online service, said: “Medical cannabis is not appropriate for everyone and prescribing decisions need to be made carefully on an individual patient basis. SureLeaf has, therefore, been designed with strong clinical safeguards and specialist oversight at every stage, so treatment is only considered for patients where it is clinically appropriate.”
Prescription of cannabis-derived medicines was legalised in 2018 after the mother of a young boy from Northern Ireland with severe epilepsy had cannabis oil seized at airport customs. Only patients with rare forms of epilepsy, certain chemotherapy side-effects or certain multiple sclerosis symptoms can receive the treatments on the NHS. Many private clinics have been treating patients with them for years. Besides chronic pain, private clinics have also been prescribing the medicines for various psychiatric disorders and neurological conditions.
This year, researchers from universities in Australia and England found “very little evidence” that cannabis was effective in treating anxiety, anorexia nervosa, psychotic disorders, post-traumatic stress disorder or opioid use disorder. They found some evidence that medical products could reduce dependence on cannabis, relieve symptoms of Tourette syndrome and help insomniacs sleep better.
Boots is launching the service alongside a collaborative research programme with the University of Nottingham that will examine patient outcomes, prescribing practices and experience in the treatment of chronic pain.
Analysis
Why This Matters
- Opens a new, widely accessible channel for medical cannabis prescriptions in the UK, potentially expanding patient access beyond private clinics.
- The high-street presence of Boots lends legitimacy to cannabis-based treatments and may reduce stigma for patients.
- The tie-in research programme with the University of Nottingham could provide real-world evidence on efficacy and safety, influencing future NHS prescribing.
Background
Medical cannabis was legalised in the UK in 2018 after a high-profile case involving a child with severe epilepsy. NHS prescribing remains tightly restricted to a few specific conditions, while private clinics have offered treatments for a broader range of disorders including chronic pain, anxiety and insomnia. The evidence base for cannabis-based medicines has been mixed, with some studies supporting their use for certain conditions and others finding limited benefit.
Key Perspectives
Boots: says the service is designed for patients who have not found relief from conventional treatments, with strong clinical safeguards to ensure appropriate prescribing.
Researchers (from universities in Sydney, Melbourne, Brisbane and Bath): found “very little evidence” that cannabis was effective for anxiety, anorexia nervosa, psychotic disorders, PTSD or opioid use disorder, but some evidence for reducing cannabis dependence, relieving Tourette syndrome symptoms and improving sleep in insomniacs.
What to Watch
- Uptake of the Boots service and any early feedback on patient outcomes.
- Whether the research programme with the University of Nottingham produces findings that affect NHS prescribing guidelines.
- Potential regulatory or professional-body responses to high-street pharmacy-led cannabis prescribing.
Checked
12 claims in this story checked against 1 source: 12 supported.
Show each claim
- SupportedBoots is to begin prescribing medical cannabis in the UK, in a first for a UK high street pharmacy.World news | The Guardian: “Boots is to start prescribing medical cannabis, it has announced, in a first for a UK high street pharmacy.”
- SupportedThe online service is for UK patients aged 25 and over with eligible conditions such as chronic pain, anxiety or insomnia.World news | The Guardian: “The online service is being offered to patients in the UK aged 25 and older who have an eligible condition such as chronic pain, anxiety or insomnia.”
- SupportedBoots chief healthcare officer Jamie Kerruish said conventional treatments do not provide adequate symptom relief for some people with ongoing pain, affecting everyday life.World news | The Guardian: “Millions of people live with ongoing pain and, for some, conventional treatments do not provide adequate symptom relief. This can have a significant impact on everyday life, from working and sleeping well to spending time with family and doing the things they enjoy.”
- SupportedBoots medical director Dr David Gwynne said medical cannabis is not appropriate for everyone and decisions need to be made carefully for each patient.World news | The Guardian: “Medical cannabis is not appropriate for everyone and prescribing decisions need to be made carefully on an individual patient basis.”
- SupportedBoots said prescriptions would be independently reviewed by a multidisciplinary team including a second independent consultant before treatment begins.World news | The Guardian: “independently reviewed by a multidisciplinary clinical team that includes a second, independent consultant, before treatment begins”
- SupportedPatients must first have tried conventional treatments without success to be prescribed medical cannabis.World news | The Guardian: “It said any patient wishing to be prescribed medical cannabis must first have tried conventional treatments without success.”
- SupportedBoots said patients would be regularly reviewed.World news | The Guardian: “And the pharmacy said patients would be regularly reviewed.”
- SupportedPatients will begin with an online assessment, then have their suitability reviewed before being invited to a video consultation with a consultant.World news | The Guardian: “Patients will be invited to start an assessment online. Their suitability will then be reviewed by a clinical team, before they are invited to a video consultation with a consultant, according to Boots.”
- SupportedPrescription of cannabis-derived medicines was legalised in 2018 after the mother of a boy from Northern Ireland with severe epilepsy had cannabis oil seized at airport customs.World news | The Guardian: “The prescription of cannabis-derived medicines was legalised in 2018 after the mother of a young boy from Northern Ireland with severe epilepsy had cannabis oil seized at airport customs .”
- SupportedOnly patients with rare forms of epilepsy, certain chemotherapy side-effects or certain multiple sclerosis symptoms can get the treatments on the NHS.World news | The Guardian: “Only people with rare forms of epilepsy, those dealing with certain side-effects of chemotherapy, and those with certain multiple sclerosis symptoms, can get it on the NHS.”
- SupportedPrivate clinics have prescribed cannabis-derived medicines for various psychiatric disorders and neurological conditions as well as chronic pain.World news | The Guardian: “But, besides chronic pain, private clinics have also been prescribing the medicines for various psychiatric disorders and neurological conditions.”
- SupportedResearchers from universities in Australia and England found “very little evidence” that cannabis was effective for anxiety, anorexia nervosa, psychotic disorders, PTSD or opioid use disorder.World news | The Guardian: “researchers from universities in Sydney, Brisbane and Melbourne in Australia, and Bath in England, found “very little evidence” that cannabis was effective in treating anxiety, anorexia nervosa, psychotic disorders, post-traumatic stress disorder or opioid use disorder.”